Suivre
Ramya Lakshminarayan
Ramya Lakshminarayan
Scientist, Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Adresse e-mail validée de Lilly.com
Titre
Citée par
Citée par
Année
Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers
R Lakshminarayan, C Wunder, U Becken, MT Howes, C Benzing, ...
Nature cell biology 16 (6), 592-603, 2014
3092014
Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells
C Boscher, YZ Zheng, R Lakshminarayan, L Johannes, JW Dennis, ...
Journal of Biological Chemistry 287 (39), 32940-32952, 2012
1162012
Analysis of Endocytic Pathways in Drosophila Cells Reveals a Conserved Role for GBF1 in Internalization via GEECs
GD Gupta, S MG, S Kumari, R Lakshminarayan, G Dey, S Mayor
PloS one 4 (8), e6768, 2009
842009
Sec24 phosphorylation regulates autophagosome abundance during nutrient deprivation
S Davis, J Wang, M Zhu, K Stahmer, R Lakshminarayan, M Ghassemian, ...
elife 5, e21167, 2016
802016
Pre-emptive quality control of a misfolded membrane protein by ribosome-driven effects
R Lakshminarayan, BP Phillips, IL Binnian, N Gomez-Navarro, ...
Current Biology 30 (5), 854-864. e5, 2020
422020
Galectins and glycosphingolipids in clathrin-independent endocytosis and cell migration
R Lakshminarayan
Paris 11, 2012
2012
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–6